Chronic Lymphocytic Leukemia Clinical Trials in Atlanta, Georgia

8 studies are recruiting for chronic lymphocytic leukemia in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

   The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Emory University Winship Cancer Institute, Atlanta, Georgia

   Locations

   130 in total

   Run by

   BeOne Medicines

   See if you can join NCT06846671 on ClinicalTrials.gov

2. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Winship Cancer Institute Emory University, Atlanta, Georgia

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

3. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

   This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Northside Hospital, Atlanta, Georgia

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07020533 on ClinicalTrials.gov

4. Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

   This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Emory University Hospital Midtown, Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT03501576 on ClinicalTrials.gov

5. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Northside Hospital, Atlanta, Georgia

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

6. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

   The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   The Emory Clinic, Atlanta, Georgia

   Locations

   38 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876649 on ClinicalTrials.gov

7. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

   Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   The Emory Clinic, Atlanta, Georgia

   Locations

   36 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876662 on ClinicalTrials.gov

8. Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

   This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in thi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Winship Cancer Institute at Emory University, Atlanta, Georgia

   Locations

   5 in total

   Run by

   Christine Ryan

   See if you can join NCT06043674 on ClinicalTrials.gov